For informational purposes only — not investment advice

← Back to signals

IQV

SHORTINSIDER SELL

IQVIA HLDGS INC

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.

Funds
3
Score
2.25
vs SPY
+19.1%
Stock return (since Q-end)
+38.8%
SPY return (since Q-end)
+19.7%
Current price
$236.66
Days to cover (short int.)
2.7d-13.3%
as of 2026-07-31

News Summary

Positive

IQVIA delivered strong organic growth with Q1-Q2 2026 revenue up 8.4-8.7% YoY, beat EPS consensus in Q2, and raised full-year 2026 guidance across revenue, EBITDA, and EPS metrics. The company successfully executed strategic acquisitions (Charles River drug discovery assets), deployed AI-native operations (192 agents across 64 use cases), and strengthened its balance sheet via euro debt refinancing, while generating robust free cash flow growth and maintaining aggressive share repurchases ($950M in H1 2026).

Funds Reducing / Exiting (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Viking GlobalAndreas Halvorsen0−619K0.4%-100%EXITED
Appaloosa LPDavid Tepper0−280K0.9%-100%EXITED
Glenview CapitalLarry Robbins0−200K1.0%-100%EXITED

Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
STAUB W RICHARDSee RemarksSELL6K$232.68$1.28M2026-08-03
Patel BhavikSee RemarksSELL2K$235.27$0.44M2026-07-31
Sherbet EricSee RemarksSELL5K$249.16$1.25M2026-07-29
Cherofsky KeriannSee RemarksSELL558$245.21$0.14M2026-07-29
BOUSBIB ARISee RemarksSELL4K$247.10$1.10M2026-07-29
BOUSBIB ARISee RemarksSELL5K$246.85$1.13M2026-07-29
BOUSBIB ARISee RemarksSELL44K$246.08$10.84M2026-07-29
BOUSBIB ARISee RemarksSELL53K$244.78$13.02M2026-07-29